Format

Send to

Choose Destination
See comment in PubMed Commons below
Joint Bone Spine. 2008 May;75(3):303-10. Epub 2007 Oct 22.

Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: A randomized, crossover study (BALTO II).

Author information

1
Philipps-University of Marburg, Department of Endocrinology, Reproductive Medicine and Osteoporosis, Baldingerstrasse, 35033 Marburg, Germany. hadji@med.uni-marburg.de

Abstract

OBJECTIVES:

Patient preference strongly influences long-term medication use in chronic diseases such as postmenopausal osteoporosis.

METHODS:

This 6-month, open-label, crossover, international study randomized 350 women with postmenopausal osteoporosis to monthly oral ibandronate 150mg for 3months followed by weekly alendronate 70mg for 12weeks, or vice versa.

RESULTS:

Of patients expressing a preference (93.1%), more preferred the monthly ibandronate regimen (70.6%) than the weekly alendronate regimen (29.4%). The monthly ibandronate preference rate was statistically significant (P<0.0001). The most common reasons for ibandronate preference were ease of staying on treatment long-term (81.5%) and better lifestyle fit (75.4%). More women found the monthly ibandronate regimen more convenient (76.6%) than the weekly alendronate regimen (23.4%). The monthly ibandronate convenience rate was statistically significant (P<0.0001). The safety profiles of the two regimens were similar.

CONCLUSION:

The strong patient preference for monthly ibandronate over weekly alendronate replicates previous study findings and may lead to improved treatment adherence in women with postmenopausal osteoporosis.

PMID:
18069036
DOI:
10.1016/j.jbspin.2007.07.011
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center